Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) announced that the company has developed a gel-like form of Oxycyte® that it intends to investigate as a topical application for open wounds, abrasions and burns. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier.

The innovation is based on technologies in-licensed earlier this year from Virginia Commonwealth University. In combination with a hydrogen peroxide pouch, researchers believe the compound could have superior abilities to deliver a high concentration of oxygen directly to the wounded tissue. The combination of Oxycyte gel and H2O2 is believed to be the key to its possible efficacy. The company intends to submit to the FDA a protocol for a proposed clinical investigation before the end of the calendar year.

“Unlike the intravenous drug application of Oxycyte in traumatic brain injury, this would be a topical application, applied to the skin or to the surface of wounds. So we’re hopeful that the clinical review process would be as a medical device, which can be shorter and faster than review as a drug,” said company chairman and CEO Chris J. Stern, DBA. “If the safety/efficacy cycle is indeed shorter, as I believe it can be, then it suggests that substantive partnering models could be launched shortly after safety and efficacy are proven. Sales of ointments, dressings, bandages, etc are counted in the high billions of dollars each year. I think that every one of these products could prove to be a candidate to carry a form of Oxycyte.

“While I’m excited about this new potential use for Oxycyte, I know that the big question on our shareholders’ minds right now is the status of our Phase IIb protocol for Oxycyte in TBI. We’re not going to get into the details of our communications with the FDA. That would not be in the best interests of the company or the process. I’ll just say that positive communications are continuing and that when there is news, we’ll announce it,” said Stern.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes. For further information, visit http://www.oxybiomed.com.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company’s judgment as of the date of this release. These statements include references to potential wound care applications of Oxycyte in treating open wounds, abrasions and burns and to expectations that the FDA will allow clinical trials and reviews to be conducted as a medical device rather than a drug. Forward-looking statements in this release also include those that suggest markets in which a wound care version of Oxycyte could be used and estimates of the cumulative size of those markets. Actual events or results may differ from the company’s expectations. There can be no assurance that the FDA will approve a protocol to conduct clinical trials for these applications, that it will allow testing and review as a medical device, and that if conducted, any clinical trials will be successful or that the FDA will approve use of Oxycyte in any formulation in the uses described in this release. Furthermore, there can be no assurance that if the FDA does approve such uses that the product will compete successfully or that sales at any meaningful levels will be reached. There can be no assurance also that the company will be able to reach or launch any partnering agreements to develop and/or market these applications of Oxycyte. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.’s business can be found in the company’s public periodic filings with the Securities and Exchange Commission, which are available via http://www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Oxygen Biotherapeutics, Inc.

New data, generated by Thomas Jung and colleagues, at Novartis Exploratory Development, Switzerland, have indicated that a drug known currently as AEB071 can reduce the clinical symptoms of psoriasis, a chronic, currently incurable autoimmune skin disease.

In the study, healthy volunteers and patients with psoriasis were administered AEB071 by mouth. Different groups of individuals received different doses of the drug, but all doses were well tolerated with no obvious side effects. The decrease in the clinical symptoms of psoriasis was associated with a decreased ability of immune cells known as lymphocytes to divide and express a soluble factor known as IL-2. The authors therefore suggest that AEB071 might be an effective new treatment for psoriasis, although they caution that further clinical trials are needed to more clearly establish that the drug is safe and effective.

“The PKC inhibitor AEB071 may be a therapeutic option for psoriasis”
Click here to view article

Journal of Clinical Investigation (JCI)

The JCI is the publication of the American Society for Clinical Investigation, an honor society of physician-scientists.

Journal of Clinical Investigation

For people experiencing hair loss, there’s a mix of encouraging and discouraging news. No drug treatments have gained FDA approval since 1997, and the most effective therapy, a hair transplant, is expensive. But transplants now offer increasingly satisfying results thanks to improved surgical techniques, and recent biotechnology discoveries may lead to less invasive treatments, reports the August 2008 issue of the Harvard Health Letter.

The FDA has approved two drugs, minoxidil (Rogaine) and finasteride (Propecia), to slow hair loss or regrow hair. Propecia is more effective than Rogaine, but it’s more expensive. A major drawback of both is that you need to keep on taking them to sustain the benefits.

Hair transplants involve removing hair follicles from the sides of the head and implanting them in bald or thinning areas. One of the main obstacles is money surgery costs $8,000 to $12,000. Transplants have improved over the years, making for a more natural hairline by continuing the trend toward smaller and smaller grafts.

Several drugs that preserve the health of hair follicles are in the pipeline. In addition, companies hope to find ways to create new hair follicles from scratch. One potential method involves using an abrasive gel to gently damage the skin and then topical cream to switch on the follicle-generating genes. Another possibility is a technique in which hair-forming cells are extracted, multiplied, and replanted into the scalp.

You can find plenty of treatments for hair loss on the Internet. Some are “specially formulated” shampoos sold along with saw palmetto herbal supplements. But there’s not much evidence that these work.

Harvard Health Publications
Harvard Medical School 10 Shattuck St., Ste. 612
Cambridge, MA 02115
United States
http://www.health.harvard.edu

View drug information on Minoxidil Topical Solution 2% for Women; Propecia.

New knowledge points to the fact that a genetically induced lack of filaggrin, a key protein of the skin barrier, plays a decisive role in the origin of allergies. In a large study on more than 3000 school-children scientists of the Helmholtz Zentrum München and the Technische Universit?t München found that about 8% of the German population carry variations of the filaggrin gene, which raise the risk to develop atopic dermatitis more than threefold. In addition, these genetic variations predispose to hay fever and asthma in those with atopic dermatitis.

Allergic diseases have increased considerably in the past decades in most industrial countries. A combination of genetic and environmentally related factors is said to be the cause. In recent years, several genes were examined for a role in allergic diseases, and one of them actually turned out to be a key player. This gene encodes filaggrin, an essential protein in the horny layer of the skin. If this protein is reduced or lacking due to a genetic defect, the natural cornification is impeded and the natural barrier function of the skin is limited.

In 2007 filaggrin mutations could be identified as cause of the so-called fish scale disease or ichthyosis vulgaris, and as risk factors for the development of atopic dermatitis, a genetic breakthrough made by the Irish research team around Irwin McLean and Alan Irvine.

In an international collaboration, Dr. Stephan Weidinger from the Technische Universitat Munchen and Dr. Thomas Illig from the Helmholtz Zentrum München now investigated 3,000 school children, representing the population as a whole. The study was carried out together with Dr. Michael Kabesch of the Children’s Hospital of the Kudwig-Maximilians-University Munich. The Munich scientists found that almost 8% of the children in Germany suffer from a genetically determined deficiency of filaggrin protein in the skin. These children have a more than threefold increased risk to develop atopic dermatitis. “In general, our results show that mutations in the filaggrin gene are extremely strong risk factors for atopic dermatitis and beyond that for hay fever. In the case of pre-existing eczema they may also cause asthma,” explained Weidinger The asthma results were especially surprising, because filaggrin is not present in the respiratory tract, but appears to be of importance in the skin only.”A weakened skin barrier function might enable allergens to penetrate more easily and thereby promote the development of allergies.”

In addition, in another recent study on 1600 adults from the KORA cohort (Co-operative Health Research in the Augsburg Region), which represents the German population as a whole, Weidinger and Illig found out that a deficiency of filaggrin protein due to genetic variants also increases the risk for allergic contact eczema, especially of allergic reactions to nickel, which is often found in costume jewelry.

The current results show that the skin plays a crucial role in the development of different allergic diseases. “We are now interested in finding out the precise consequences of filaggrin mutations,” declared Illig. “The next thing to do is to examine the metabolic pathway of this important protein. In addition, we want to clarify which molecular mechanisms play a role at the genetic level, but also concerning the protein itself. Then, the final aim, of course, is to find a therapy for patients with atopic diseases,” added Illig. “If a lack of filaggrin is such an important factor in allergic diseases, it would be almost conceivable to increase production of this protein or to replace its function in other ways”.

HELMHOLTZ ZENTRUM MUENCHEN - GERMAN RESEARCH CENTRE FOR ENVIRONMENTAL HEALTH
Ingolstaedter Landstra?e 1
D-85764 Neuherberg
http://www.gsf.de

A revolutionary dissolvable scaffold for growing new areas of skin could provide a safer, more effective way of treating burns, diabetic ulcers and similar injuries.

This ultra-fine, 3-dimensional scaffold, which is made from specially developed polymers, looks similar to tissue paper but has fibres 100 times finer. Before it is placed over a wound, the patient’s skin cells (obtained via a biopsy (1)) are introduced and attach themselves to the scaffold, multiplying until they eventually grow over it. When placed over the wound, the scaffold dissolves harmlessly over 6 to 8 weeks, leaving the patient’s skin cells behind.

This new approach to skin reconstruction has been developed by a team of chemists, materials scientists and tissue engineers at the University of Sheffield, with funding from the Engineering and Physical Sciences Research Council. It is designed primarily for cases involving extensive burns where surgeons are unable to take enough skin grafts from elsewhere on the body to cover the damaged areas. Currently, bovine collagen (2) or skin from human donors is used in these cases, but these approaches have potential health and rejection risks.

“Simplicity is the key,” says Professor Tony Ryan, who is leading the team. “Previous attempts to find better ways of encouraging skin cell growth have used chemical additives and other elaborate techniques to produce scaffolds, but their success has been limited. We’ve found that skin cells are actually very ’smart’ it’s in their DNA to sort themselves into the right arrangement. They just need a comparatively uncomplicated scaffold (and each other) to help them grow in a safe, natural way.”

The polymers used in the scaffold are biodegradable materials already approved for medical applications. Because the team has recognised that skin cells are ’smart’ and the scaffold can therefore be ‘dumb’ (i.e. not overly sophisticated), simple polymers can be used.

The process for making the scaffolds is based on the well-known technique of electrospinning (3). However, the team has made a key advance by developing a new method of making, from the same biodegradable polymers, aligned-fibre ‘mats’ of potential use in promoting nerve or tendon growth. This method is currently being patented.

The next step in the research is to develop the skin reconstruction technology for clinical use, hopefully in the next few years. The technology also offers possibilities for testing the toxicity of cosmetic and similar products, using materials grown in the laboratory that closely resemble natural skin.

“Ultimately, we can envisage treatment of burns victims and the undertaking of reconstructive surgery using the scaffold and the patient’s own skin to produce bespoke skin for that patient,” says Professor Ryan. “As an accident-prone mountain biker, I find that prospect very attractive!”

ENGINEERING AND PHYSICAL SCIENCES RESEARCH COUNCIL (EPSRC)
Polaris House
North Star Avenue
Swindon
SN2 1ET
http://www.epsrc.ac.uk

The New York Times on Monday examined how “dermatology is fast becoming a two-tier business in which higher-paying customers” seeking cosmetic procedures “often receive greater pampering” than “medical patients for whom health insurance pays fixed reimbursement rates.”

According to the Times, dermatology is one of the specialties in which patients “are not only willing to pay for quality-of-life treatments that may not be covered by insurance,” but also are willing to pay “much more for such treatments than insurers would pay for a medical procedure that takes a similar amount of time.” Health insurers typically reimburse a physician $60 to $90 for a visit that includes a full-body skin cancer check, which takes about 10 minutes. Dermatologists might receive $500, paid on the day of treatment, for a Botox injection to the forehead that takes 10 minutes.

The Times reports that some dermatologists have separate waiting and examination rooms for cosmetic and medical patients. In addition, some dermatologists offer additional services — such as valet parking — for cosmetic patients. Donald Richey, a California dermatologist, said, “Cosmetic patients have a much more private environment than general medical patients because they expect that,” and physicians “are a little bit more sensitive to their needs.” Richey said his efforts to cater to cosmetic patients do not hinder the level of care for medical patients and noted that he keeps walk-in times available to see medical patients.

A study published last year in the Journal of the American Academy of Dermatology found that dermatologists in 11 U.S. cities and one county offered appointments to patients seeking Botox sooner than patients inquiring about a changing mole, which is a possible sign of skin cancer. The study also found some dermatologists are staffing nurse practitioners and physicians’ assistants, known as physician extenders, to primarily see medical patients.

Mixed Message?
According to the Times, as “dermatologists are trying to advance the idea of a national skin cancer epidemic, such a two-tier system is raising concerns that the coddling of beauty patients may divert attention from skin diseases.” Several people interviewed by the Times said dermatologists they saw for medical reasons treated them as potential cosmetic patients.

Davis Pariser, a dermatologist and president-elect of the American Academy of Dermatology, said, “The message is that the cosmetic patient is more important than the medical patient, and that’s not a good message.” Julie Cantor, a lawyer and medical school graduate who teaches a medical ethics course at the University of California-Los Angeles, said, “If you really started treating patients differently based on their ability to pay out of pocket, that’s a real problem,” adding, “People who want their wrinkles fixed to go to a wedding should not be treated better than those who have psoriasis” (Singer, New York Times, 7/28).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Botox Cosmetic.

The New York Times on Monday examined how “dermatology is fast becoming a two-tier business in which higher-paying customers” seeking cosmetic procedures “often receive greater pampering” than “medical patients for whom health insurance pays fixed reimbursement rates.”

According to the Times, dermatology is one of the specialties in which patients “are not only willing to pay for quality-of-life treatments that may not be covered by insurance,” but also are willing to pay “much more for such treatments than insurers would pay for a medical procedure that takes a similar amount of time.” Health insurers typically reimburse a physician $60 to $90 for a visit that includes a full-body skin cancer check, which takes about 10 minutes. Dermatologists might receive $500, paid on the day of treatment, for a Botox injection to the forehead that takes 10 minutes.

The Times reports that some dermatologists have separate waiting and examination rooms for cosmetic and medical patients. In addition, some dermatologists offer additional services — such as valet parking — for cosmetic patients. Donald Richey, a California dermatologist, said, “Cosmetic patients have a much more private environment than general medical patients because they expect that,” and physicians “are a little bit more sensitive to their needs.” Richey said his efforts to cater to cosmetic patients do not hinder the level of care for medical patients and noted that he keeps walk-in times available to see medical patients.

A study published last year in the Journal of the American Academy of Dermatology found that dermatologists in 11 U.S. cities and one county offered appointments to patients seeking Botox sooner than patients inquiring about a changing mole, which is a possible sign of skin cancer. The study also found some dermatologists are staffing nurse practitioners and physicians’ assistants, known as physician extenders, to primarily see medical patients.

Mixed Message?
According to the Times, as “dermatologists are trying to advance the idea of a national skin cancer epidemic, such a two-tier system is raising concerns that the coddling of beauty patients may divert attention from skin diseases.” Several people interviewed by the Times said dermatologists they saw for medical reasons treated them as potential cosmetic patients.

Davis Pariser, a dermatologist and president-elect of the American Academy of Dermatology, said, “The message is that the cosmetic patient is more important than the medical patient, and that’s not a good message.” Julie Cantor, a lawyer and medical school graduate who teaches a medical ethics course at the University of California-Los Angeles, said, “If you really started treating patients differently based on their ability to pay out of pocket, that’s a real problem,” adding, “People who want their wrinkles fixed to go to a wedding should not be treated better than those who have psoriasis” (Singer, New York Times, 7/28).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Botox Cosmetic.

Barrier Therapeutics, Inc. announced the introduction of Xolegel CorePak™ for the treatment of seborrheic dermatitis. Now, patients with this chronic skin condition need only one prescription to get quick itch relief and to safely manage the overall condition long term.

The two products in Xolegel CorePak are new Xebcort™ Gel, a 1% hydrocortisone gel, and Xolegel® (ketoconazole, USP) Gel, 2%. Xebcort Gel provides quick symptom relief and is presented as a 0.8 ounce tube designed for short term use to relieve itch. Xolegel CorePak contains 45 grams of Xolegel Gel provided in three 15 gram tubes. In a long-term safety trial with Xolegel Gel, patients remained symptom free for up to 8 weeks post-treatment.

“By providing the hydrocortisone and ketoconazole gels separately in one prescription, Xolegel CorePak encourages patients to comply with their physician’s recommendations to better manage this chronic and common inflammatory skin condition,” explained Al Altomari, Chief Executive Officer of Barrier Therapeutics.

About the Xolegel Family of Products

With the addition of Xolegel CorePak, there is now a family of Xolegel products available to treat the variety of seborrheic dermatitis patient types.

Xolegel Gel is a cosmetically elegant treatment which offers powerful relief for seborrheic dermatitis of the face and body in immunocompetent adults and children 12 years of age and older. Xolegel Gel is a patented topical formulation of 2% ketoconazole in a translucent, non-greasy gel. Xolegel Gel applies smoothly and dries clear. With its unique gel formulation, Xolegel Gel provides patients with a dosing regimen of a once daily application for only 14 days, thus reducing by approximately 75 percent the number of applications required by other topical antifungal seborrheic dermatitis therapies. Xolegel Gel was approved by the FDA in July 2007 and is the first and only FDA-approved prescription gel formulation of ketoconazole.

Xolegel Duo™, available by prescription, also consists of 45 grams of Xolegel (ketoconazole, USP) Gel, 2% provided in 15 gram tubes, and one 1.7 ounce bottle of Head & Shoulders® (pyrithione zinc 1%) anti-dandruff shampoo. It is designed to provide a more complete treatment option for effectively managing seborrheic dermatitis by providing a prescription gel formulation of ketoconazole for the face and body plus a medicated shampoo for the scalp in one convenient package. All Xolegel products are covered under the company’s Patient 1st Program. The program allows most commercial insurance patients to receive their prescription for one $10 copay. For additional information on the entire family of Xolegel products, visit http://www.xolegel.com

About Seborrheic Dermatitis

Seborrheic dermatitis is a common inflammatory skin condition characterized by a red, scaly, itchy rash primarily occurring on the face, scalp, hairline, eyebrows and torso. Seborrheic dermatitis affects approximately three to five percent of the U.S. population, or 8.5 million people. An estimated 90% of seborrheic dermatitis patients reportedly have affected areas on the scalp as well as on the face and/or body. There is no known cause, cure or way of preventing seborrheic dermatitis but it can be effectively managed. Traditional prescription therapies for this condition have consisted primarily of shampoos, topical antifungal creams and topical steroids that typically require two or more applications per day over periods of up to four weeks to be effective.

About Barrier Therapeutics

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three prescription pharmaceutical products in the United States: Xolegel® (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion® (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and superficial fungal infections. The company is headquartered in Princeton, New Jersey and has a wholly-owned subsidiary in Geel, Belgium. More information about Barrier Therapeutics can be found on its corporate website at: http://www.barriertherapeutics.com. Xolegel, Vusion, Solage, Xolegel CorePak and Xolegel Duo are all trademarks of Barrier Therapeutics, Inc.

Safe Harbor Statement

In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the “Safe Harbor” provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Barrier’s current expectations or forecasts of future events. Barrier’s performance and financial results could differ materially from those reflected in these forward-looking statements due to the marketplace acceptance of Barrier’s products, Barrier’s ability to execute its commercial and clinical strategy, the decisions of regulatory authorities, the results of clinical trials, and strategic decisions regarding its pipeline, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries generally. For a discussion of these and other risks and uncertainties that may effect the forward-looking statements, please see the risk factors in the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 which is on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Barrier undertakes no obligation to update publicly any forward-looking statement.

Barrier Therapeutics

Dr. Michael Law, a board certified plastic surgeon in Raleigh, North Carolina, sees patients from all parts of the world seeking natural looking plastic surgery. “Fat grafting has changed the results of facial plastic surgery dramatically. Traditional facelifts simply do not provide the natural result of microfat grafting,” says Dr. Law.

Fat grafting has been performed by plastic surgeons for decades. There is no question that fat is the ideal material for soft tissue augmentation, and that the results obtained with fat grafting are the most natural-appearing. However, one problem with this procedure in years past has been resorption (breakdown) of the grafted fat, so that the resulting improvement is not permanent. The grafted fat must gain its own blood supply in its new location in order to persist long-term, and this generally is not possible when large amounts are injected at once and when specialized instrumentation and techniques are not employed.

A relatively new technique has been developed called structural fat grafting, lipostructure, or microfat grafting, in which small amounts (less than 0.1 cc at a time) of fat are carefully microinjected in a series of discrete layers to gradually ‘build’ new soft tissue structure. As there is space between each microinjection, new blood vessels are able to grow into the grafted fat, allowing it to persist.

This is a procedure that requires specialized training and specialized surgical instruments, as well as patience and attention to detail on the part of the surgeon. When lipostructure or microfat grafting is performed properly, permanent improvements in facial plastic surgery are possible.

Structural fat grafting can be performed on eyelid hollows, to fill sunken cheeks, for filling sunken tear troughs under the eyes and is often used for blepharoplasty correction when too much skin and or fat has been removed in an eyelid surgical procedure. Some people who have experienced fat loss as a result of procedures such as IPL or Thermage can also benefit greatly from permanent fat injections.

Michael Law MD (Aesthetic Plastic Surgery)
www.michaellawmd.com

A senior lecturer at the University of Huddersfield recently celebrated the publication of her first book.

Dr Karen Ousey, of the Department of Adult and Children’s Nursing in the School of Human and Health Sciences, co-edited the textbook with former Huddersfield academic Dr. Caroline McIntosh,

Entitled Lower Extremity Wounds: A Problem-Based Approach, the book is the first of its kind that has been written as a joint venture by experienced nurses and podiatrists, all with expert knowledge in wound care. Aimed at both students and practitioners, the book is described as “essential reading” for anyone involved in lower extremity wound care.

It highlights the importance of multi-professional collaboration to encourage the crossing and dismantling of professional boundaries, to increase understanding of each other’s roles, and to ensure that the patient receives the best available evidence-based interventions during their health care journey.

Lower limb wounds are frequently observed in clinical practice and often present a real challenge for health care practitioners. Lower extremity wound care requires a multidisciplinary approach involving a number of different health care professionals in order to achieve optimum patient care. Nurses and podiatrists, in particular, are frequently involved in the assessment and management of lower extremity wounds, often working in partnership.

Taking a problem-based learning approach, each of the ten chapters of the text highlight best practice in the management of wounds by type, discusses clinical guidelines and current evidence, and links this theory to a clinical scenario thus bridging the theory to practice gap.

The School of Human and Health Sciences at the University recently hosted a one day summer conference focussing on the assessment, diagnosis and management of diabetic foot ulcers. The day was sponsored by Molnlycke Health Care and attracted over 90 registered nurses and podiatrists.

The day was opened by Professor Richard White, the first Professor in Tissue Viability from the University of Worcester. Prof White delivered the keynote speech, discussing the use of soft silicone dressings and other speakers included Dr. Caroline McIntosh, National University of Ireland, Galway; Paul Chadwick Diabetes Specialist Podiatrist, Salford and Una Adderley Tissue Viability Prescribing Specialist Nurse, North Yorkshire and York PCT. The day was chaired by Dr Karen Ousey from the Department of Adult and Children’s Nursing, University of Huddersfield.

“The Department of Adult and Children’s Nursing is working closely with the Division of Podiatry in developing inter-professional education between nurses and podiatrist in the field of wound care, said Dr Ousey. “It is hoped that if the two professional groups learn together they will appreciate each others roles and work in a seamless fashion within the clinical areas administering effective evidence based care to their clients.”

Lower Extremity Wounds: A Problem Based Approach (Paperback)
by Karen Ousey (Editor), Caroline McIntosh (Editor)
Paperback: 310 pages
Publisher: WileyBlackwell (7 Dec 2007)
Language English
ISBN-10: 0470059087
ISBN-13: 978-0470059081
– Click here to view the relevant Amazon (UK) web page
– Click here to view the relevant Amazon (USA) web page

University of Huddersfield Queensgate Huddersfield
West Yorkshire
HD1 3DH
UK
http://www.hud.ac.uk